Frontiers in Pharmacology (Aug 2021)
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
- Ganglin Su,
- Ganglin Su,
- Ganglin Su,
- Ganglin Su,
- Tianshu Liu,
- Xiaohong Han,
- Hao Sun,
- Hao Sun,
- Hao Sun,
- Wenan Che,
- Kun Hu,
- Kun Hu,
- Kun Hu,
- Junwen Xiao,
- Junwen Xiao,
- Junwen Xiao,
- Yanfeng Li,
- Yanfeng Li,
- Yanfeng Li,
- Yuchen Liu,
- Yuchen Liu,
- Yuchen Liu,
- Wujiao Li,
- Wujiao Li,
- Hongbing Mei,
- Hongbing Mei,
- Hongbing Mei
Affiliations
- Ganglin Su
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Ganglin Su
- Shantou University Medical College, Shantou, China
- Ganglin Su
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Ganglin Su
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Tianshu Liu
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Xiaohong Han
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Hao Sun
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Hao Sun
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Hao Sun
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Wenan Che
- Hunan Key Laboratory of Economic Crops Genetic Improvement and Integrated Utilization, School of Life Sciences, Hunan University of Science and Technology, Xiangtan, China
- Kun Hu
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Kun Hu
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Kun Hu
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Junwen Xiao
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Junwen Xiao
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Junwen Xiao
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Yanfeng Li
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Yanfeng Li
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Yanfeng Li
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Yuchen Liu
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Yuchen Liu
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Yuchen Liu
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Wujiao Li
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Wujiao Li
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Hongbing Mei
- Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Hongbing Mei
- Key Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- Hongbing Mei
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- DOI
- https://doi.org/10.3389/fphar.2021.709548
- Journal volume & issue
-
Vol. 12
Abstract
Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of “mRNA surveillance pathway,” “RNA degradation,” and “RNA transport” in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.
Keywords
